Amex Hearing and Delist
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported):
October 26, 2005
Commission
File No. 1-14778
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1691
Michigan Ave., Suite 435
Miami,
FL
|
|
33139
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(305)
534-3383
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item 3.01.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On
October 26, 2005, the Company received notice from the American Stock Exchange
("Amex") staff indicating that the Company no longer complies with Amex's
continued listing standards because the Company had shareholders' equity of
less
than $6.0 million and losses from continuing operations and/or net losses in
its
five most recent fiscal years, as set forth in Section 1003(a)(iii) of the
Company Guide, and that the Amex intends to proceed with removal of the
Company's common stock from listing and registration on Amex. The Company has
appealed this determination and requested a hearing before a committee of the
Amex. There can be no assurance that the Company's request for continued listing
will be granted.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Exhibit
No. Title
99.1 Press
Release issued by the Company dated November 1, 2005.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA,
INC.
By:
/s/
Michael T. Sember
Name:
Michael T. Sember
Title: President and Chief Executive Officer
Dated: November
1, 2005
Exhibit
Index
Exhibit
Number Description
of Exhibits
99.1 Press
Release of Registrant dated November 1, 2005